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ABSTRACT 
 
Introduction: The rising cost of prescription drugs in the United States has become a concern for patients, 
prescribers, payers and policy makers. Prescription medications comprise an estimated 10-14% of overall 
personal health care services in the United States, and drug spending is projected to grow at a faster rate than 
overall healthcare expenditures in the coming years, comprising an increasingly larger percentage of our nation’s 
health care expenditure. With the introduction of specialty medications (e.g. direct-acting antivirals for Hepatitis 
C and oral chemotherapy agents), traditional-cost containment strategies are no longer sufficient, necessitating 
the use of novel managed care strategies to improve patient outcomes and decrease costs. 
 
Methods: A comprehensive literature review was conducted utilizing electronic databases to describe traditional 
cost-containment strategies and uncover innovative strategies currently being implemented in the Hepatitis C 
and oral chemotherapy space. Key payer stakeholders (public and private payers, self-funded payers, health 
systems, integrated delivery networks, and pharmacy benefits managers) were engaged in in-depth, semi-
structured interviews to validate the findings of the literature review. Additionally, payers were invited to discuss 
current and future innovative managed care cost-containment strategies that are being implemented or 
developed in real-world pharmacy practice. 
 
Results: Four categories of managed care clinical programs were identified that have a clear impact on clinical 
and financial outcomes associated with the management of Hepatitis C and oral chemotherapy products. These 
strategies include: (1) task-shifting, (2) medication optimization with refill outreach, (3) oral chemotherapy 
programs, and (4) oncology financial assistance programs. Each type of strategy was examined to describe 
program impact, application and effectiveness as a managed care solution. These strategies were then validated 
by key payer stakeholders, uncovering additional cost-saving mechanisms related to: (1) traditional managed 
care strategies, (2) CMS policies and programs, (3) value-based contracting, (4) pharmacy benefit design, and 
(5) future cost savings measures under development. These mechanisms were examined to identify health policy 
recommendations. 
 
Conclusions: As the United States moves towards a value-based healthcare system, innovative cost-
containment strategies that utilize clinically-oriented, outcomes-based metrics and approaches will increasingly 
become standard pharmacy practice as physicians strive to maximize value-based reimbursements while payers 
seek to balance access and affordability. The managed care solutions detailed in this study validate cutting edge 
pharmacy practice advancements that can improve health outcomes while more effectively controlling overall 
healthcare expenditures. Healthcare- and formulary-decision makers (as well as policy makers) can use the 
findings of this study to begin implementing innovative managed care pharmacy practice models and drug 
utilization review solutions to contain the rising cost of specialty drugs. 
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INTRODUCTION 
 
The rising cost of prescription drugs in the United States has become a concern for patients, prescribers, 
payers and policy makers. The Department of Health and Human Services (DHHS) Office of the Assistant 
Secretary for Planning and Evaluation (ASPE) estimates that prescription medications, both retail (drug spending 
at outlets that directly serve patients) and nonretail (spending by medical providers for drugs they provide directly 
to patients) comprised 16.7% of the estimated $2.729 trillion spent on overall personal health care services in 
the United States in 2015.1 In the 1990s, prescription drugs typically accounted for 7% of healthcare spending, 
indicating the rapid growth in proportion of pharmacy spend in recent years. This rapid growth underscores the 
importance of prescription drugs as a potential contributor to long-term growth in overall healthcare costs. The 
National Health Expenditure Accounts (NHEA) projects that total personal health care services will rise by an 
average of 5.2% annually until 2018.1 Since the ASPE indicates that prescription drug spending will grow at a 
faster pace of 7.3% annually, prescription drugs are projected to comprise an increasingly greater percentage of 
all health care spending in the coming years.1 
 
The IQVIA Institute for Human Data Science, 
a reliable source of information on prescription 
drug expenditure, conducted a National 
Prescription Audit (NPA) between the years of 
2009 and 2015.2 The IMS NPA data on 
prescription expenditures represents 
nationally projected estimates based on a 
sample of 46,400 chain store, independent 
store and food store pharmacies. The audit 
shows that both estimated expenditures and 
number of prescriptions increased 
substantially during the audit period (Table 1). 
The total number of prescriptions rose from 
3.54 billion to 3.95 billion, an 11.6% increase; 
whereas, the total retail prescription drug 
expenditure rose from $255.3 billion to $356.7 
billion, a 39.7% increase.2 These figures 
indicate that drug expenditure rose 3.5-fold 
faster than number of prescriptions. Viewed from another perspective, the cost per prescription rose 25% from 
$72.12 in 2009 to $90.30 in 2015, suggesting that drug price inflation is largely a result of increasing drug 
prices rather than growth in the volume of prescriptions.2 
 
For this very reason, rising drug prices are currently under scrutiny as the focus of a variety of research and 
conversations. According to the HHS ASPE, an analysis of factors underlying the rise in prescription drug 
spending from 2010 to 2014 identified that 30% is due to either changes in the composition of drugs prescribed 
toward higher price (brand or specialty) products or price increases for drugs that together drove average price 
increases in excess of general inflation.1,3 The ASPE also explains that expenditures on specialty drugs generally 
appear to be rising more rapidly than expenditures on other drugs, also contributing to the increase in prescription 
pharmaceutical spend. 1 
 
As the drug pricing landscape has evolved, payers and other various stakeholders have made efforts to 
develop managed care strategies to control drug spend. Typically, these cost-containment strategies have 
been categorized in one of three broad themes: utilization strategies, pricing strategies and regulatory 
strategies.11 In 2005, the Kaiser Family Foundation completed a comprehensive literature review to address drug 
spending growth and evaluate strategies that public and private payers were implementing to control growth in 
drug spending (Supplemental Material, Table 6). The report is very thorough and provides detailed descriptions 
of over 30 specific cost control strategies, ranging from market-based approaches intended to affect which and 
how many drugs patients use (e.g. prior authorization, step edits) to restrictions on pharmacy networks and 
government mandated price regulation. 
 
 
 Expenditures 
(Billions $) 
Prescriptions 
(Billions) 
Expenditure/Rx 
($) 
2009 $255.3 3.54 $72.12 
2010 $261.2 3.54 $73.79 
2011 $276.6 3.57 $77.48 
2012 $280.9 3.71 $75.71 
2013 $297.1 3.81 $77.98 
2014 $329.9 3.92 $84.16 
2015 $356.7 3.95 $90.30 
% 
difference +39.7% +11.6% +25.2% 
Table 1. Retail expenditures and prescription from 2009 to 2015.1 
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In recent years, with the introduction of expensive specialty drugs, biologics and biosimilars, payers have been 
forced to develop newer and more innovative methods of controlling drug costs. The potential impact that these 
expensive new drugs could have on our healthcare system is devastating. However, some costly drugs may 
offer reasonable value. At first glance, sofosbuvir (Sovaldi), a 12-week treatment for the Hepatitis C Virus (HCV), 
is simply another medication contributing to the issue, with a total price tag of $84,000 ($1000 per tablet).12 
Despite the astronomical price of sofosbuvir, this treatment was found to be a cost-effective treatment for HCV 
when taking into consideration the patient’s lifetime horizon and a societal perspective. Furthermore, a study 
was conducted that showed Medicaid programs were able to spend an estimated $1.1 billion (after discounts) 
on sofosbuvir with no additions to their budgets.12 This finding highlights the need to understand factors that 
contribute to recent medication price inflation while evaluating expenditures on these prescription drugs to ensure 
that they are equivalent with their value, affordable to the health care system, and equitable for all parties 
involved. 
 
As the United States health care system transitions towards value-based care (VBC), providers will receive 
reimbursements based on patient outcomes, known as value-based payments. In this VBC model, it is in the 
provider’s best interest to minimize costs while ensuring proper health outcomes—two goals that clinical 
pharmacists can assist providers in achieving. The role of the clinical pharmacist as an integral member of the 
health care team has been proven to improve overall health outcomes and lower costs through optimization of 
medication use. The impact that pharmacists can have in a clinic setting is due in large part to the occurrence of 
improper and unnecessary medication use. In 2015, prescription drug spending totaled $325 billion of the total 
$3.2 trillion United State (US) healthcare expenditure. A similar proportion of the total healthcare expenditure, 
$300 billion, was spent on health care costs resulting from the improper and unnecessary use of medications. 
These figures suggest that for every dollar spent on a prescribed medication, another dollar is spent addressing 
a medication related problem. Pharmacists’ interventions can address this unnecessary expenditure while 
ultimately improving patient outcomes and managing total cost of care. 
 
The current drug pricing landscape necessitates further research into novel cost-containment strategies 
that can assist policy makers and other stakeholders in better understanding the various innovative 
approaches that will become a requirement to control drug expenditure in a healthcare environment that 
is progressively being consumed with pharmacy spend. Pharmacists are in a position to have significant 
influence over the drug spend for patients, highlighting the need to utilize their expertise to connect medication 
optimization to total cost of care. Moreover, in an environment where sensitivity towards the cost of medicines is 
increasing, drug price inflation is a serious concern. This study seeks to identify innovative cost-containment 
strategies through a comprehensive literature review validated by in-depth interviews with key opinion leaders 
and other stakeholders in order to recommend future policies that can be employed to control drug cost by 
improving patient adherence, clinical outcomes and reducing the total cost of care. 
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METHODS 
 
A literature review was conducted to develop a baseline understanding of the US drug pricing landscape while 
also identifying historically utilized cost-containment strategies & uncovering newer, more innovative managed 
care strategies being implemented – from the clinic setting to national health policy. This literature search was 
limited to Hepatitis C & oncology as these disease states are managed with expensive specialty medications 
that require careful population health and utilization management strategies to contain costs. The literature 
review was conducted utilizing three major electronic databases using a variation of the following search terms: 
(“high cost drugs” OR “pharmaceutical expenditure” OR “financial toxicity”) AND (“managed care” OR “cost-
containment strategies”) AND (“Hepatitis C” OR “oral oncology”). The initial search results returned 615 related 
articles, which were filtered to a total 135 articles. These articles were abstracted to identify four common cost-
containment strategies implemented in the clinic. Each type of strategy was examined to describe impact, 
application and effectiveness as a managed care solution. 
 
There are many innovative practice models incorporating unique managed care strategies to contain the cost of 
drugs that are not yet described in literature, and an efficient way to uncover these is to engage in discussions 
with key stakeholders. The second phase of this project was a qualitative study in which payers were engaged 
in semi-structured interviews in order to contextualize findings from the literature review and identify feasible 
implementation strategies while uncovering further innovative strategies not identified in literature. A total of 8 
formulary decision-makers (public and private payers, self-funded plans, health systems, integrated delivery 
networks & pharmacy benefits managers) consented for a phone interview. No compensation was provided for 
participation. Each payer participated in an in-depth, semi-structured, 60-minute interview conducted by a senior 
research associate and a student pharmacist during July and August 2018. Interviews were recorded and 
transcribed, and subjects were de-identified before analysis. Responses were coded into themes and organized 
into a data abstraction matrix for comparison across themes and payer types. 
 
 
RESULTS 
 
PHASE I: COMPREHENSIVE LITERATURE REVIEW 
 
The comprehensive literature review uncovered a variety of strategies with variable effectiveness in containing 
costs associated with the treatment of Hepatitis C and cancer. Data abstracted from the review identified four 
categories of managed care strategies that can have a clear impact on clinical and financial outcomes associated 
with these specific patient populations: (1) task-shifting, (2) medication optimization or refill outreach, (3) oral 
chemotherapy programs, and (4) oncology financial assistance programs. 
 
Task Shifting with 2nd Generation Direct-Acting Antivirals for the Management of Hepatitis C 
 
According to the CDC, an estimated 3.2 million people are living in the United States with chronic Hepatitis C 
Virus (HCV).16 An estimated 80% of these people remain untreated, which can be attributed to under-diagnosis 
of HCV as well as barriers to treatment access. These barriers include both the high cost of therapy and limited 
availability of workforce available to deliver care.17 Standard of care direct-acting antivirals (DAAs) are expensive 
drugs, deterring patients from receiving life-saving medications, which can ultimately lead to more costly 
comorbidities (e.g. cirrhosis, hepatocellular carcinoma, liver transplantation).18 Additionally, the specialists that 
manage this condition (hepatologists, gastroenterologists, infectious disease specialists) typically practice at 
urban referral medical centers that are geographically separated from HCV patients in medically underserved 
areas, whom remain outside the continuum of HCV care.19 
 
To combat these barriers to treatment, clinics have been developed that utilize task-shifting to empower more 
abundant and accessible local non-physician healthcare providers to deliver HCV care to patients earlier in their 
disease course. In one such model, implemented by Stanford University Medical Center licensed vocational 
nurses and support staff manage the treatment of HCV patients taking 2nd generation direct-acting antivirals 
(DAAs).18,19 Logistics (Figure 1) for this devolved HCV clinic structure include: 
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• Specialist physicians (hepatologists) traveled 
to three hepatology outreach clinics (in 
medically underserved areas of California that 
were located roughly 200 hours from their 
academic medical center) for three full clinic 
days each month to screen patients and enroll 
them in the study. 
• Patients initiated on 2nd generation DAAs 
received routine follow-up telephone calls 
from licensed vocational nurses and support 
staff to confirm regimen adherence and 
tolerance throughout duration of treatment. 
• Labs were communicated to the specialists 
via a shared electronic medical record (EMR). 
Critical lab results or concerning symptoms 
were shared immediately with specialists via 
pager. 
• Specialists were available for urgent or 
scheduled follow-up appointments throughout 
treatment course. 
• Specialists assessed patient outcomes 12 
weeks after completion of therapy to 
determine curative endpoint of viral clearance(known as sustained viral response at 12 weeks, SVR-12). 
 
In this devolved task-shifting model, 88% of HCV patients achieved the curative endpoint of undetectable HCV 
RNA 12-weeks after completion of therapy (SVR-12).19 This clinic structure was projected to decrease incidence 
of decompensated cirrhosis by 71%, hepatocellular carcinoma by 63%, liver transplantation by 71%, and liver-
related death by 68%, consistent across all sub-populations of patients (treatment-naïve non-cirrhotic, treatment-
naïve cirrhotic, treatment experienced non-cirrhotic, treatment experienced cirrhotic). Clinic capacity was 
assumed to be double that of a clinic supporting 1st generation DAAs, and reductions were realized in on-
treatment monitoring costs of 56% and total lifetime costs of 20%.18 
 
Overall, the treatment effectiveness results of this task-shifting model are comparable to pivotal clinical trials for 
these 2nd generation DAA-based regimens, and to “real-world” experiences at tertiary care centers in the US. As 
evidenced above, the task-shifted treatment model achieved these results in a cost-effective manner that 
realized savings for all HCV patient subgroups. 
Figure 1. HCV clinic structure incorporating task-shifting from 
HCV specialist at an urban academic medical center to LVN at 
multiple rural clinics in medically underserved areas.18 
EHR,
Pager
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Two-tiered Outreach Program for the Management of Hepatitis C 
 
Second generation DAAs offer improved cure rate and greater tolerability compared to previous HCV regimens. 
However, their exorbitant costs are detrimental to patients, health care systems & health plans. A recent analysis 
estimates that these novel DAAs will cost payers $136 billion over the next 5 years, $61 billion of which will be 
paid by the government.21 In addition to cost concerns, nonadherence is a known issue for patients on these 
complex and toxic medications that offer a high pill burden and a variety of drug-drug interactions (DDIs). 
 
The University of Massachusetts Medical School’s 
Clinical Pharmacy Services developed a solution 
that addressed both of these known issues by 
providing cost-effective care and adherence 
support provided by pharmacists.22 Their 
comprehensive HCV medication management 
program utilized a two-tiered approach to identify 
patients that could benefit from (1) regimen 
optimization and (2) refill reminders followed by 
provider and patient outreach (Figure 2). 
 
In the first tier, pharmacists used HCV guidelines 
published by the American Association for the Study 
of Liver Diseases and Infectious Disease Society of 
America (AASLD/IDSA) to develop detailed prior 
authorization (PA) criteria that were then utilized to 
identify patients during the PA review process with 
regimens that could be optimized for efficacy, safety and cost. All regimen optimization recommendations were 
based on consensus guideline criteria for genotype, liver fibrosis staging, and prior treatment history, and were 
required to provide similar or improved cure rates at a lower cost than originally prescribed regimens. 
Consideration of DDIs and clinical rationale was also incorporated into the PA review process. Of the 911 PAs 
that were approved, pharmacists identified 25% (223) as meeting the criteria for medication optimization, which 
included changing medications, treatment duration or both. Pharmacists provided recommendations to the 
prescribing physicians, whom accepted 65% (135) of pharmacist-recommended interventions. The most 
common regimen change was shortened duration of therapy (55 of 135 regimen changes).22 
 
In the second tier, pharmacy claims history was used to identify patients who were nearly or past due for a refill. 
Pharmacy technicians would then contact the prescriber to facilitate the refill process. A total of 515 members 
were included in the refill outreach program and were informed of an upcoming or past due refill of their HCV 
medication. Of these, 101 patients had subsequent PA modifications (e.g. PA closed due to treatment 
deferral/adverse events/hospitalization or PA extended due to prescriber extending treatment or start date) and 
414 members subsequently completed refills for their HCV medications.22 
 
As a result of this two-tiered pharmacist-led outreach program, total cost avoidance of $3.8 million was realized, 
the majority of which resulted from shortening Harvoni treatment duration from 12 to 8 weeks (with no decrease 
in SVR-12). After subtracting program costs during the study period, the program demonstrated an ROI of $10.28 
for every $1 spent.22 
  
 
Figure 2. Two-tiered comprehensive HCV medication management 
program with corresponding PA modification.22 
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Oral Chemotherapy Program Incorporating Collaborative Practice Agreement Protocol with Medication 
Therapy Management Services 
 
The use of oral chemotherapy increased from 5% of chemotherapeutic agents administered in 2003 to 25% 
administered by 2010.23 Although this formulation has improved convenience and quality of life compared to 
chemotherapy infusions, non-adherence to oral medications is a challenge that compromises treatment 
outcomes. Muluneh et al. from the University of North Carolina (UNC) Lineberger Cancer Center developed a 
30-question survey to analyze patients’ use of oral chemotherapies and identify opportunities to improve 
adherence.24 This study found that there are three main barriers that prevent patients from optimal oral 
chemotherapy at-home adherence: misunderstanding about the timing of drug with food, difficulty understanding 
labeling directions, and stopping drug without informing physicians. These findings indicate that a 
multidisciplinary approach is needed to optimize adherence & improve outcomes. 
 
Subsequent to this survey study, UNC’s Lineberger Cancer Center implemented an oral chemotherapy program 
with comprehensive pharmacy services and assessed the program’s impact on oral chemotherapy adherence 
in program participants.25 In this innovative pharmacy practice model, an ambulatory care oncology clinical 
pharmacist practitioner (CPP) works collaboratively with the healthcare team (including prescribing physician 
and specialty pharmacy) through a collaborative practice agreement (CPA) protocol to offer mediation therapy 
management (MTM) services throughout the treatment period (Figure 3). These services included medication 
access assistance, initial and continued education and counseling, side effect monitoring and management, refill 
outreach, etc. The clinical pharmacist developed protocol with the attending physician to allow for increased 
pharmacist follow-up at each clinic visit, enabling MTM services to have a greater impact on patient outcomes. 
Adherence was estimated using the medication possession ratio (MPR), which was calculated by the sum of 
days supply divided by the total number of days in the period. 
The goal MPR was greater than 90% as these patients had 
chronic myeloid leukemia (CML) and in this patient population 
an MPR of less than or equal to 90% was associated with vastly 
reduced outcomes. The mean MPR was found to be 0.92, which 
was above the established adherence threshold.25 Additionally, 
current survey results were compared with an historical survey 
control. This comparison identified an improvement in self-
reported adherence as less patients admitted to reducing their 
oral chemotherapy dose without first consulting their doctor and 
more patients reported that dose reductions were indeed at the 
direction of the physician. 
 
This is an oncology clinic structure that lacks financial evidence 
in the literature. However, the clinical outcomes illustrate the 
impact that pharmacy services have when integrated into daily 
clinic structure with routine, scheduled touch points between 
clinical pharmacists and patients. Future research should focus 
on quantifying financial impact in order to expand MTM billing 
and independent prescribing protocols. 
  
 
Figure 3. Overview of services offered by 
pharmacist (PharmD) and clinical support staff 
in the management of oncology patients.25 
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Oncology Financial Assistance Programs 
 
Financial toxicity is among the many outcomes that result from the use of chemotherapeutic agents in the US. 
Unfortunately, the costs of these drugs have experienced an exponential increase over the past half a century, 
and with the introduction of oral formulations, traditional payment structures are no longer effective.28,29 The high 
prices of orally available cancer drugs coupled with increasing out-of-pocket costs for patients through higher 
deductibles and co-insurance have made it difficult for patients to afford these life-saving medications. 
 
In an effort to improve access to care, pharmaceutical companies have developed financial assistance programs, 
either directly or through affiliated non-profit pharmaceutical foundations. These programs offer copay coupons, 
copay assistance, pricing discounts and direct grants to patients. Manufacturers also offer in-kind gifts of drug 
supplies free of charge to patients with proven financial need through initiatives called Pharmaceutical 
Assistance Programs (PAP). 
 
In order to quantify and characterize the 
number and monetary value of drugs received 
through PAPs, Mitchell et al. studied cancer 
patients treated at an academic, state-
supported, public hospital network.30 This 
study found that of the 215 patients utilizing 
PAP services at the study hospital, even privately insured patients participated in these PAP programs, as 14% 
of patients receiving free drugs were insured, 46% had public coverage, and 40% were uninsured. It was also 
identified that 40% of the retail value of drugs obtained via PAP at this health system was attributable to imatinib 
and dasatinib, both of which are orally administered chemotherapy, and 75% came from oral chemotherapeutics 
as a class (Table 2). This study provides evidence that as oral chemotherapy prices continue to rise while also 
making up a larger proportion of pharmacy expenditure, less patients, including those with insurance, are able 
to afford them. These patients are forced to find ways to gain access to care—PAP being one such avenue. 
 
PAPs are known for being relatively opaque regarding eligibility and 
benefits. Zullig et al. conducted a study to identify the degree of 
financial assistance provided by PAPs.31 This retrospective study used 
data from an academic cancer center’s specialty pharmacy to 
determine prescription chemotherapeutic costs and PAP coverage. 
Study authors identified that 12% of all oncology prescription claims 
were eligible for PAP from 2013 to 2015. Of these 8,212 prescriptions 
that received PAP assistance, the median amount of financial 
assistance provided by PAPs was 15% of the median prescription cash price. Explained another way (Table 3), 
98% of drugs covered under PAPs received less than 25% coverage through the PAP program. A small minority 
of prescriptions received financial assistance from PAPs, and the proportion of financial assistance receives was 
small relative to the price billed to insurance. This study illustrates the modest role that PAPs play in reducing 
anticancer prescription-related costs. 
 
Many cancer institutions have dedicated personnel that guide patients through aspects of care, including 
financial concerns. These “oncology navigators” assist patients with PAP applications and coordinate monthly 
prescription fulfillment for PAP patients. Spencer et al. conducted a study to assess these navigators’ perception 
of their patients’ financial burden and their role in addressing financial needs.32 A total of 78 navigators responded 
to the survey, reporting that 75% of their patients experienced some degree of financial toxicity related to their 
cancer. Of the 78 responders, 12% reported that 100% of their patients experience cancer-related financial 
toxicity and 45% indicated that most of their patients are able to get some type of financial assistance. Navigators 
reported obstacles to obtaining financial assistance including insufficient resources or patient ineligibility for 
existing resources, lack of patient and provider knowledge and awareness about existing financial assistance 
programs, and application complexity requiring unnecessary or duplicative effort. These obstacles highlight the 
need for system improvements that increase patient and provider communication about financial needs in order 
to properly identify patients experiencing financial toxicity. These improvements should be combined with 
increased numbers of oncology navigators and other trained staff to connect patients with financial distress to 
existing resources. 
Uninsured Public Private 
40% 46% 14% 
Total PO Imatinib Dasatinib 
$7,373,741 $1,556,575 $1,449,633 
Total PO + non-PO       $9,798,632 
Table 2. Results of the Mitchell et al. study.30 
PAP Coverage 
(% Rx $) n % 
0% 7261 89% 
0-25% 806 9% 
25%-50% 118 2% 
  Table 3. Proportion of prescription 
  covered by PAP.31 
 Muller  -  page 10 
 
RESULTS 
 
PHASE II: QUALITATIVE PAYER INTERVIEWS 
 
In-depth, semi-structured interviews were used to validate the importance of implementing population health 
strategies (discussed above) in the clinic as a bottom-up approach to reducing total cost of care. More 
interestingly, these interviews uncovered payers’ opinions regarding current issues and hot topics in the US 
healthcare system. Transcript coding and data abstraction resulted in payer responses related to the following 
five cost-saving mechanisms: (1) traditional managed care strategies, (2) CMS policies and programs, (3) value-
based contracting, (4) pharmacy benefit design, and (5) future cost savings measures under development. The 
remainder of this manuscript discusses a description of each of these categories, incorporating payer opinions 
throughout.  
 
 
Traditional Managed Care Strategies are Effective 
 
Public, private & self-funded payers as well as pharmacy benefits managers utilize Drug Utilization Review (DUR) 
programs to check each member’s prescription at the point of sale to identify potential problems with the 
prescription before it is filled. If an issue is identified during the claim adjudication process, an edit (e.g. rejection 
message) is sent to the dispensing pharmacist to notify them of the issue before the patient receives the 
medication. There are two types of concurrent DUR edits: soft & hard. Soft edit rejections can be overridden by 
the pharmacy. Hard edit rejections cannot be overridden by the pharmacy and require a prior authorization from 
the plan. These hard edits stop the adjudication of the claim until the payer has signed off to actually pay for the 
medication. 
 
“[Hard edits] absolutely work with specialty drugs. If you want me to pay $300,000 per year for your 
medication, I have the right to see that it is actually being utilized appropriately. 
 – Self-funded payer 
 
Prior authorization, step therapy & quantity limits are examples of hard edits. These DUR tools, along with a 
variety of other tried-and-true managed care strategies (below) remain effective in today’s payer world. The 
majority of these started with public payers (CMS) and were later adopted by commercial and self-funded plans. 
 
• Prior authorization (PA) – Before a plan will cover a particular specialty drug, the member’s prescriber 
must first show that the patient has a medically necessary need for that particular drug and have met the 
PA requirements for the drug.  
• Step therapy – This is a type of PA in which the plan requires the patient to try a less expensive drug on 
the plan’s drug list (formulary) that has been proven an effective treatment for the condition prior to 
moving up a “step” to a more expensive drug. Usually step therapy edits are utilized to drive prescribing 
habits towards generic alternatives and away from high-cost branded/specialty drugs. 
• Quantity limits – For safety and cost reasons, a plan may limit the monthly quantity of drug that can be 
dispensed. If a patient requires 60 tablets per month of a drug with a quantity limit of 30 tablets per month, 
their prescriber will need to communicate with the plan to get authorization for a higher quantity. This tool 
is utilized to reduce unnecessary or superfluous prescribing. 
• Split fill programs – This tool is utilized for specialty medications that are known to be poorly tolerated. 
Payers design the PA with a quantity limit of enough days supply to ascertain whether the patient can 
tolerate the medication or not (e.g. 1 week). This decreases costs and minimizes wasted drug supply. 
• Preferred drug list (PDL) – A list of medications that the plan will cover the cost for without the prescriber 
having to request a PA. Typically these lists are comprised on generic substitutes or branded products 
for which the plan negotiated a cost-effective price with the pharmaceutical company. The PDL limits the 
drugs that may be prescribed, especially with our CMS patients. Public payers report that the public 
perception of specialty drugs on the PDL is that manufacturers are giving state-funded plans a great price 
for an otherwise exorbitantly priced drug; however, this is usually not the case. This false perception often 
increases utilization of expensive drugs, ultimately negatively impacting our public health plans. 
• Formulary design – Health plans have pharmacy & therapeutics (P&T) committees that develop a list 
of prescription drugs, both generic and brand name, to identify preferred agents that offer greatest overall 
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value for the plan in terms of safety, efficacy and cost. Payers include manufacturer rebates into this cost-
effectiveness analysis; however, policy changes are currently on Capitol Hill that could disrupt this 
analysis. Most private payers have multiple formularies that vary in quantity of PAs & step edits, premiums 
& co-insurance, etc. 
• Premium, deductible, copay, co-insurance, out-of-pocket maximum – These tools are utilized in 
pharmacy benefit design to help distribute healthcare costs across the entire health plan. In theory, this 
creates a risk pool that is averse to high-cost claims submitted by a small minority of patients utilizing 
specialty drugs and should help shield this minority from catastrophic expenses. However, in practice, as 
specialty drug prices skyrocket this minority is stuck with exponentially increasing co-insurance fees. 
• Tiering – A pharmacy benefit design that financially rewards patients for using generic and preferred 
drugs by requiring the patient to pay progressively higher copayments for preferred non-preferred and 
brand name drugs. Specialty medications generally fall in Tier 4 or 5, higher tiers that also include drugs 
that are injected or infused, have unique storage or shipment requirements, are enrolled in REMS 
programs, or are not stocked at retail pharmacies. 
• Distribution channel – Most specialty medications are distributed through a limited channel of specialty 
pharmacies (SPs) selected by the manufacturer for their high-quality medication adherence tracking, 
patient follow-up, patient education programs, financial assistance programs, etc. As we move towards 
a value-based healthcare system, higher quality care across the entire patient journey is crucial. 
Integrated delivery networks and large health systems are now getting a piece of the pie by contracting 
with manufacturers to distribute specialty medications through their own in-house SPs. 
 
Payers of all plan types agree that these traditional managed care strategies are essential with the caveat that 
innovative solutions are desperately needed to better control specialty drug expenditure as prices skyrocket. 
 
 
Centers for Medicare & Medicaid Services (CMS) Policies & Programs Stifle Pricing Negotiations 
 
The federal government signed Medicare and Medicaid into law in 1965, and for 50 years these programs have 
been protecting the health and wellbeing of Americans. As healthcare evolves and therapeutic advancements 
are made in the form of specialty medications, payers deem some of the CMS policies and programs to be 
antiquated and unfit for the growing market. 
 
The Medicaid Drug Rebate Program is an agreement between CMS and participating drug manufacturers to 
help offset the Federal and state costs of most outpatient drugs dispensed to Medicaid patients. In exchange for 
offering predetermined drug rebates on a quarterly basis, drug manufacturers are given access to Medicaid 
formularies and PDLs. When manufacturers sign this agreement, state Medicaid plans must cover most of the 
manufacturer’s drugs, stipulations withheld. Public payers say that this program minimizes the levers they can 
pull to manage the impact of drug expenditures. Medicaid plans are not given the option to negotiate pricing and 
are instead forced to cover drugs with a rebate determined by Federal statutory formulas. (For innovator drugs, 
the rebate is defined as 23.1% of the Average Manufacturer Price.) Public payers also state that this program is 
not compatible with the Affordable Care Act (ACA) Medicaid Expansion. As Medicaid membership expanded by 
approximately 15 to 20 million, manufacturers were required to offer these rebates to a larger proportion of 
covered lives. Public payers describe this as a loss that deters brand product manufacturers from lowering drug 
prices. As a result, in recent years Massachusetts embarked on a policy change to address the issues with the 
rebate program. The state Medicaid plan submitted an amendment to establish a closed formulary, giving them 
the look and feel of a commercial plan with the power to negotiate rebates. However, the federal government 
shut this movement down. 
 
“Regarding Hepatits C drugs – due to CMS policies and programs, we really only had 2 options to mitigate 
financial impact to our budget: PDL and rebates that were are not legally allowed to negotiate.” 
– Public Payer 
 
Congress enacted the Medicaid best price law in 1990 as a means of ensuring that Medicaid receives the best 
price to conserve tax dollars and provide health coverage to the poorest among us. The law requires drug 
manufacturers to charge the Medicaid program the lowest (“best”) price they negotiate with any payer. 
Commercial payers say that this is noble in theory; however, in practice it is a proven driver of higher medication 
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costs and can stifle innovative payment models outside of Medicaid, ultimately leaving consumers worse off. 
Self-funded and commercial payers agree that the best price law deters experimentation with value-based 
contracting because if manufacturers offer them a money-back guarantee based on outcomes, the 
manufacturers would also have to agree to give away drug free of charge to every state Medicaid program. It is 
the payer’s opinion that drug manufacturers are unwilling to do this (for obvious reasons); therefore, discouraging 
innovative, outcomes-based payment models. 
 
“The best price rule deters manufacturers from wanting to engage in value-based contracts with us.” 
– Private Payer 
 
 
Payers Perceive Many Road Blocks with Value-Based Contracting 
 
Value-based care (VBC) is a shift in our healthcare system towards a model that rewards physicians for 
coordinating care in such a way that is achieves specific clinical outcomes. In this model, providers’ 
compensation is based in part on keeping a population healthy, not just on the quantity of labs or procedures 
they order. The pharmaceutical industry would love to partake in this evolving model, especially with high-cost 
specialty medications; however, as previously described, outdated CMS programs and policies deter such 
actions.  
 
This is a complex reimbursement model that would require careful management by physicians and close follow-
up by payers and manufacturers to confirm the occurrence of pre-specified clinical endpoints as described in 
every VBC contract. Multiple payers used the example of high-cost PCSK-9 inhibitors for the treatment of primary 
hyperlipidemia, describing that in a VBC contract for evolocumab or alirocumab, the manufacturer would agree 
to rebate an additional 5% on top of the contractually agreed upon standard rebate if the patient does not reach 
target LDL goals as defined in the contract. However, the agreement is not that simple because the contract 
would include a clause stating that the patient must follow contractually agreed upon treatment protocol (e.g. 
maintain adherence to the intervention and must also be concomitantly prescribed a high-intensity statin that 
does not interact with the selected PCSK9 inhibitor). If the patient is found to be non-adherent or improperly 
following the treatment standards, the manufacturer would no longer pay the additional 5% rebate to the payer. 
 
Payers agree that, in addition to regulatory issues, many hurdles exist along the path towards value-based 
contracting for specialty medications. Some examples are as follows: 
 
• Resource intensive for all parties – The VBC reimbursement model demands a large amount of 
resources from both the payer and manufacturer to monitor patient adherence & track clinical endpoints. 
• Data management & health privacy issues – Payers agree that they would be skeptical to allow 
manufacturers to collect and analyze outcomes data, and vice versa. Neither party would be able to hand 
off data to each other due to laws that protect health information. Payers agree that a third-party data 
aggregator could be an appropriate middleman to formally evaluate clinical efficacy, but they are unsure 
as to who would pay the third-party vendor. 
• Perceived lack of manufacturer risk based on clinical trials – Payers report that manufacturers are 
only willing to agree to VBC terms that utilize endpoints as they were defined in the manufacturer’s clinical 
trials. Payers say that clinical trial outcomes have a statistically significant chance of occurring, and they 
would rather agree to terms that increase manufacturer risk. Instead of agreeing to outcomes that secured 
FDA approval, payers would appreciate manufacturers assuming more risk by agreeing to payment terms 
that improve upon clinical trial data. A private payer suggested that agreeing to incorporate outcomes 
exactly as they appear in clinical trials is equivalent to health plans supporting additional ongoing clinical 
studies while the manufacturer follows patients to publish more real-world evidence supporting the use 
of their drug. 
• Disapproval of annuity payment design – Some VBC agreements would allow health plans to pay for 
drug over time as outcomes come to fruition. It is agreeable that at first glance this appears to be very 
helpful as it would improve payer cash flow. However, public payers say that health plans are not in the 
business of finance and they are not interested in an annuity payment for specialty medications. This 
payer gave the example of student loans, saying that lower payments over a longer period of time initially 
seems affordable, but when you run the numbers you are paying far more in the long-term. 
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• Beneficiary retention fluctuates based on eligibility changes – Beneficiaries switch between health 
plans as their eligibility changes. If a commercial beneficiary loses his job and joins the state’s Medicaid 
plan, would Medicaid be stuck with paying the remainder of a specialty drug claim accrued under the 
commercial plan with an annuity payment reimbursement design? For example, if at the time of the 
beneficiary’s switch to Medicaid the commercial plan had paid 50% of a $1 million claim for Luxterna, 
which party would pay the remaining 50%? The commercial plan would not want to pay for a drug that 
benefits a patient that is no longer in their risk pool, and Medicaid would not want to pay for a claim that 
they were not involved in accruing. 
 
“There’s a lack of trust – I don’t trust pharma to manage the data & pharma doesn’t trust me to do it.” 
– Private Payer 
 
“We aren’t in the business of financing or layaway, so annuity payments don’t make sense to us.” 
– Public Payer 
 
“[Manufacturers] are making a bet that they have a statistically significant chance of winning, as they proved 
in [their] clinical trials.” 
– Private Payer 
 
 
Implementation of Innovative Pharmacy Benefit Design Is Necessary as Drug Prices Soar 
 
As previously mentioned, traditional pharmacy benefit design using tried and true managed care principles is 
still considered an effective tool. However, just like some Federal drug pricing regulations, these principles could 
benefit from an innovative and creative update in order to more appropriately manage specialty drug prices. 
Payers provided the following examples as methods they are using to re-work traditional pharmacy benefit 
design in a manner that is mutually beneficial for the consumer and the health plan. 
 
Traditionally, when a commercial patient uses a copay card the manufacturer’s payment counts towards the 
patient’s deductible and annual out-of-pocket maximum (MOOP). After the annual limit is reached, the plan pays 
for 100% of prescription drug costs. However, plans are evolving to utilize two alternative approaches to adjust 
how they engage with manufacturer’s copay offset programs. 
 
• Copay accumulator program – The commercial health plan does not let the manufacturer’s payments 
count towards the patient’s deductible and annual MOOP obligations. Instead, these payments cover the 
cost of each prescription until the maximum value of the copay offset program is reached. For example, 
a manufacturer offers a copay card that reduces the patient’s copay to $5 at point-of-sale (with a total 
value of $1200 on the card) for a drug that costs $200 per month. The copay card will cover 100% of the 
drug cost for six months, costing the patient $30 total. However, in this program the card’s $1200 does 
not contribute to the patient’s deductible and MOOP; therefore, after the copay card is fully depleted at 
month six the patient is stuck funding 100% of the bill ($200 per month) until they fulfill their deductible 
and MOOP, at which point the plan steps in to cover 100% of prescription drug costs. This type of program 
assists patients for the first few months, while the copay card maintains a balance. But after the total 
value is depleted, the patient is likely unable to afford the medication. 
• Copay maximizer program (also known as variable copay program) – Similar to the accumulator 
program, the manufacturer’s payments do not count towards the patient’s deductible or annual OOP 
obligations. However, instead of utilizing the copay card’s total value within the first 6 months, the plan 
distributes the maximum value of the manufacturer’s copayment program evenly throughout the benefit 
year. In the case of the example above, the plan would let the copay card contribute $100 per month for 
the 12-month benefit period, leaving the patient with a $5 copay for the entire year in addition to 100% 
of the monthly remainder ($100) until the deductible and MOOP are met, at which point the plan steps 
in to cover 100% of the prescription drug costs, respectively. 
 
Payers endorse the copay maximizer program as a strategy that has a huge economic impact, resulting in 
approximately 50% reduction in plan costs for prescription specialty drugs. If you follow the economics, the plan 
appreciates a lesser costs savings with the maximizer model compared to the accumulator, but the patient’s best 
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interests are more closely met with the maximizer model. 
Health plans also endorse other innovative pharmacy benefit design techniques, including: 
 
• “Lifestyle drugs” coverage carve out – One self-funded payer has decided to exclude an ever-
expanding list of “lifestyle drugs” from contributing to a patient’s MOOP. Simply put, the pharmacy benefit 
has coded drugs for conditions like erectile dysfunction and infertility so that members pay 100% co-
insurance. The payer explained this decision, saying that the health plan’s premium should not be 
increased for a very finite number of people’s elective drug utilization. 
o E.g. ED, infertility 
• Drug-specific coverage carve out – The same self-funded payer also heavily relies on efficacy data to 
exclude coverage for certain drugs that it deems ineffective or not clinically impactful. Tamiflu is one 
such example that the payer provided. Ultimately, if prescribed properly, Tamiflu shortens flu symptoms 
by 12-24 hours at the end of the infection. Furthermore, it is only effective if prescribed in the first 48 
hours after onset of symptoms. Many patients wait until day four or five to seek medical attention, at 
which point the physician has missed the window of opportunity. However, most prescribers in the 
emergency department will still prescribe Tamiflu regardless of symptom onset, simply to appease the 
patient in front of them by providing them with a prescription in exchange for the hours they spent waiting 
in the emergency department. 
• Site-of-care billing determination for cost effectiveness – One PBM explained that they put a block 
in place to require a PA for specific medications to allow the claim adjudicator to determine the most cost 
effective site-of-care for billing purposes (e.g. medical vs pharmacy). The PBM is able to decide whether 
it is cheaper to bill the provider or the pharmacy benefit, therefore reducing the cost of the medication. 
 
“We don’t want our members to be disadvantaged and stuck with a high deductible and OOP maximum 
while we benefit from the manufacturer’s copay card.” 
– Self-funded Payer 
 
“[Pharma] created the copay card program. I’m just taking advantage of it. They can’t stop me from creating 
a work around anymore than I can stop them from offering copay cards. 
– Private Payer 
 
 
Future Cost Savings Measures Under Development 
 
Payers of all types expressed excitement for the future of healthcare and the potential impact on improving value 
while decreasing costs. The programs and advancements listed below were commonly mentioned:  
 
• Genetic testing will play a larger role in drug utilization – As innovative therapies with high price tags 
come to market, it is crucial that our healthcare players ensure that they are utilizing these therapies 
appropriately. Biomarkers are increasingly being employed to predict the clinical impact of a medication 
on an individual patient based on their genetic makeup. Developments in this space are allowing the 
selection of specialty therapies to be tailored based on presence of genetic mutations. As biomarkers are 
developed and genetic testing becomes standard practice in specialty utilization, high upfront costs will 
be rewarded with improved downstream cost-effectiveness by avoiding specialty utilization in patients 
who are unlikely to respond appropriately. Payers report that as they currently engage with providers, 
they are aware that they are paying for genetic testing, they are simply unaware of the results due to poor 
electronic medical interface. 
• Improved EMR interface to achieve better outcomes and quality measures – Payers agree: the 
more information, the better. However, obtaining the information is difficult. One private payer explained 
that they are currently scrubbing EPIC to gain pertinent information that can help process PAs and allow 
patients access to medications without having to fill out a form. They are confident that in 2019 payers 
will begin to receive more robust lab data and by 2020 genetic testing will be commonly communicated 
between provider to payer, all in an effort to improve outcomes and quality of care. 
• Self-administered biosimilars will make the “interchangeable” conversation relevant – Unlike 
small molecule therapies that are primarily prescribed for self-administration by the patient, many biologic 
therapies are IV infusions administered in a medical facility under direct supervision by a physician. Thus, 
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pharmacy substitutions may not be particularly relevant for biologics. Additionally, it is still not clear 
whether approval of a biosimilar as “interchangeable” for a single indication will automatically afford the 
biosimilar approval for all indications for the reference product, or if the biosimilar applicant will still have 
to provide sufficient evidence pertaining to each indication. Furthermore, biosimilar applicants will have 
to determine whether the investment in additional studies to achieve interchangeable status will provide 
a better return than investing in patient and physician education and marketing of noninterchangeable 
biologics. Regardless, if self-administered biosimilars with interchangeable status enter the market, 
outpatient pharmacies may gain the authority to substitute less costly products for high-priced innovator 
biologics, effectively reducing total cost of care. 
• Leverage 340B pricing with patient incentives – Health systems and PBMs agree that 
disproportionate share hospitals with in-house outpatient pharmacies are situated to appreciate large 
cost savings. These hospitals are 340B eligible, meaning a large proportion of their patients are Medicaid 
and low-income Medicare patients, and they can purchase drugs at a reduced price. Regulatory 
requirements state that this cost savings must be reinvested back into the hospital to improve quality of 
care for this disproportionate share patient population. Some health systems have taken advantage of 
this cost savings in a legal manner by creating programs that enroll their publicly funded patients and 
encourage them to seek care from 340B eligible providers in an effort to capture close to 100% of their 
prescriptions at in-house 340B eligible pharmacies. As lawmakers discuss concerns regarding hospital 
compliance with the Federal 340B Drug Pricing Program, payers alike are unsure if this program will 
remain as effective in reducing drug costs as it currently is. 
 
 
LIMITATIONS 
 
In the broad context of the history of the pharmaceutical industry as a whole, exorbitantly high-priced drugs are 
a newly introduced and growing concern. Although there are several specific examples of successful managed 
care strategies implemented to manage the cost of these drugs, this field of study is fairly new. Many of these 
cost containment strategies are in their infancy and thus a proper assessment of financial and clinical outcomes 
is yet to be seen.  The qualitative semi-structured interview portion of this study was developed to address this 
limitation, with the hopes of uncovering information that has not yet been published but that is still pertinent to 
suggesting future drug cost-containment policies. Biologics and biosimilars are large players in the high-cost 
drug landscape, and as more biosimilars are brought to market it will be interesting to see how they are regulated 
and what impact they may have on managed care decision-making. 
 
The second phase of this research project was dependent upon data collected through in-depth interviews, and 
thus, a potential pitfall to consider is bias. The interviewer or interviewee might want to “prove” that an innovative 
cost-containment strategy is working, causing responses to be biased. Responses from stakeholders may also 
be biased due to their stake in the program of discussion. Every effort was made to minimize bias during each 
interview by creating an interview guide with pre-specified interview protocol and assembling a variety of 
interviewees to get broad perspective. 
 
Clinical and cost-effectiveness research (e.g. ICER) has recently been the center of discussions aimed at 
improving the relevance and consistency of outcomes in comparative effectiveness research. In 2016, the 
Institute for Clinical and Economic Review (ICER) opened its value framework to public comment as part of a 
planned update to ICER’s methods.13 Changes have been proposed and ICER is currently working to respond 
to these comments, indicating that this update will take place in 2017-2019. Improvements will certainly be made 
in best practices to using and evaluating evidence as the foundation for a more effective and sustainable health 
care system. However, the implications that this may have on the research conducted in this study are uncertain 
as cost-effectiveness models may change. Nonetheless, improving the relevance and consistency of outcomes 
in comparative effectiveness research go hand-in-hand with managing drug expenditure in an effort to contain 
overall cost of care.14 
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CONCLUSIONS 
 
As the price of specialty drugs continue to increase, providers will gradually be forced to implement managed 
care clinical programs to effectively and efficiently contain drug costs in order to get the most out of value-based 
reimbursements. The policies suggested from this study’s findings are applicable to these physicians and 
associated managed care organizations, ultimately helping to accomplish the Triple Aim (improving the quality 
of care, lowering overall healthcare costs, improving the patient experience), specifically lowering the per 
member per month cost of care. From the patient’s perspective, drug costs are consuming a larger proportion of 
their monthly budgets and, for some, have reached a point that is not sustainable, forcing them to forego care. 
Therefore, new pharmacy practice models and system level managed care strategies must be implemented that 
incorporate innovative cost-containment mechanisms. This study identifies four innovative managed care clinical 
programs and additional cost-saving mechanisms that can be used to suggest future drug pricing policy initiatives 
to lower total cost of care while improving patient’s access, adherence and overall health outcomes. 
 
Task shifting is a safe, effective, convenient & cost-effective, decentralized DAA-based treatment model for 
patients with HCV in medically underserved areas. Although no HCV task-shifting studies were found that 
incorporated pharmacists in the care of HCV patients through the duration of their treatment, authors of this 
study agree that the skills of this healthcare professional could be leveraged to improve outcomes and decrease 
costs. Furthermore, task-shifting is a model that has previously been shown to be effective in the management 
of patients with HIV/AIDS. North Carolina is a state that provides another example of utilizing task-shifting to 
allow pharmacists to practice at the fullest extent of their license. The North Carolina Board of Pharmacy created 
the Clinical Pharmacist Practitioner (CPP) designation which allows pharmacists to operate under a protocol 
agreement with a supervising physician to manage specific medical conditions and place orders for specific 
prescription medications and labs. This fully developed and state-supported task-shifting model gives less costly 
mid-level providers the autonomy to manage chronic conditions, freeing up physicians to function at the top of 
their licenses as well. Therefore, the implementation of similar practice models that incorporate task-shifting of 
traditionally specialist-controlled responsibilities to pharmacists in the management of other chronic diseases 
which also experience barriers to access would be an interesting field of study to develop future cost-containment 
managed care solutions. 
 
As evidenced by the University of Massachusetts Medical School’s Clinical Pharmacy Services’ $3.8 million total 
cost avoidance, comprehensive medication management programs that include both regimen optimization and 
refill outreach can lead to drastic cost savings while also ensuring that members have access to the most 
clinically appropriate regimen. Utilizing evidence-based guidelines to create detailed PA criteria allows clinicians 
to easily and systematically identify high-risk patients towards whom targeted interventions can have the greatest 
impact—an impact felt by payers, providers and patients. Many high-cost specialty drugs can benefit from the 
development of disease-state specific comprehensive management programs that ensure optimal use of therapy 
in indicated patient populations. Managed care organizations and health plans should allocate resources to 
identifying specialty medication / disease state combinations that would realize the highest cost-savings from 
consensus guideline-directed systematized regimen optimization and refill outreach programming. 
 
Oral chemotherapy programs incorporating CPAs with MTM services have been proven to improve adherence 
and overall patient outcomes. Integrated pharmacy services provided by an oncology pharmacist in collaboration 
with physicians and specialty pharmacies enhance the role of a pharmacist in patient education and across the 
total continuum of care. This is yet another managed care strategy that can be layered on top of an existing clinic 
structure, ultimately reducing total cost of care. Further research should be conducted in this space to provide 
prospective reporting and assessment of the clinical and financial impact that these services have on patient 
care. 
 
As the costs of novel oral oncology agents increase and affordability for patients with & without insurance 
becomes a larger issue, PAP programs are increasingly less capable of assisting with access to care. This is a 
cost-containment strategy that offers modest financial benefits and may be unsustainable as drug prices continue 
to soar. Despite the uncertainty of future PAP sustainability, system improvements could be made in the short-
term to better connect patients experiencing financial toxicity with existing resources earlier in their course of 
treatment. Clinic development and implementation of screening tools that increase patient/provider 
communication about financial need while assessing financial distress at an early care visit, as well as periodic 
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follow-up by navigators or trained staff throughout the care process, can more effectively and efficiently identify 
these patients and connect them with existing resources. 
 
Balancing access and affordability in the specialty arena is a complex and multi-factorial endeavor that 
necessitate novel cost-containment strategies, as evidenced by discussions with payers. Public policies can 
provide direct support to these novel strategies in ways that affect the drivers of health by reducing barriers, 
creating opportunities or providing incentives to payers and manufacturers. Policy suggestions based on payer 
insights include the following: 
 
• If Medicare and Medicaid plans were allowed to negotiate drug prices with manufacturers and maintain 
closed formularies like their commercial & global counterparts, US drug prices would certainly decline. 
• The Medicaid best price rule creates significant disincentive for manufacturers to offer outcomes-based 
pricing schemes and requires an act of Congress to exclude value-based contracting from this policy. If 
value-based contracting were excluded from this outdated policy, manufacturers and payers alike would 
have adequate incentive to dedicate resources to progressing this cause. 
• As value-based contracting progresses, payer & manufacturer consensus regarding endpoints will be 
based on per drug negotiations and will require equal assumption of risk from both parties. Policy should 
drive experimentation in this space to encourage mutually beneficial negotiations between payers and 
manufacturers. 
• Third-party data aggregation and fluctuation of beneficiary retention are large issues that discourage VBC 
& need to be addressed with policy changes. 
• One potential solution to payer’s disapproval of VBC annuity payment reimbursement design would be 
to allow Medicaid plans to pay 100% of upfront costs and leave the manufacturer on the hook to 
reimburse the state’s portion (35%) while keeping the Federal portion (65%) if clinical endpoints are not 
met. 
• Payers should be allowed to engage with manufacturers copay cards; however, the financial result must 
be in the best interest of the patient. Policy to address copay accumulator programs and encourage 
copay maximizer programs would aid in this journey. 
• National analyses should be conducted to identify site-of-care billing determination for cost-effectiveness 
across the board with specialty medications. The disparity between the two costs for a single drug warrant 
further research. 
• As technology advances, policy should reflect the increased need for protected health information and 
encourage payers and manufacturers to share this information in a secure manner to facilitate VBC and 
improved quality of care. 
• Biomarkers are an essential component of driving appropriate specialty drug utilization. Policy should 
reflect this trend and encourage payers and prescribers to support genetic testing as a necessary 
expense before selecting a specialty medication. 
• Generic competition is an effective method of containing costs. In the specialty arena, biosimilars have 
yet to see an equally effective impact on the cost of innovator biologics. Policy changes are occurring to 
address this issue and encourage pursuit of interchangeable status. However, the response is slow and 
greater incentives may be necessary to bring manufacturers on board. 
 
As the United States moves towards a value-based healthcare system, innovative cost-containment strategies 
that utilize clinically-oriented, outcomes-based metrics and approaches will increasingly become standard 
pharmacy practice, improving health outcomes while more effectively controlling healthcare expenditures. The 
strategies and policy suggestions identified and described in this study have real-world applicability. These 
managed care solutions help validate cutting edge pharmacy practices while providing implementation and future 
policy suggestions. As our nation’s healthcare structure moves towards a value-based care model, providers will 
be forced to figure out ways to effectively and efficiently manage drug costs in order to maximize 
reimbursements. Healthcare- and formulary-decision makers alike can utilize the findings in this study to 
implement innovative manage cared and drug utilization review solutions to contain the rising cost of specialty 
drugs. 
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SUPPLEMENTAL MATERIAL 
 
Table 6. The Kaiser Family Foundation published this exhaustive list of cost-containment strategies in 2005. The 
aim of this study is to evaluate these approaches and uncover new innovative strategies that better address the 
changing environment of drug prices. 
 
 
 
 
 
 
 
 
 
Utilization	Management	Approaches Cost	Charing	Approaches
Prior	authorization	requirements Copayments	as	a	general	strategy
Step	therapy	or	fail-first	requirements Tiered	copayments	in	general
Therapeutic	substitution	or	therapeutic	intervention Three-tiered	copayments
Closed	formulary Four-tiered/more	complex	copayment	structures
Preferred	drug	list	or	open	formulary Coinsurance
Mandatory	generic	substitution Reference	pricing
Management	of	specialty	drugs
Provider	financial	incentives
Payments	to	pharmacies	as	incentives
Other	coverage	management	approaches
General	Utilization	Review	Strategies Education	Strategies
Retrospective	drug	utilization	review
Physician	profiling
Drug	utilization	review	targeted	to	high-cost	users
Disease	management
Education	of	consumers	and	physicians	on	the	
benefits	of	generic	drugs
Education	of	consmers	and	physicians	on	the	
appropriate	use	of	particular	drugs
Counter	detailing	or	academic	detailing
Development	of	unbiased	information	on	the	
appropriate	use	of	certain	drugs
Utilization	Strategies A	variety	of	market	
based	approaches	
intended	to	affect	
which	and	how	many	
drugs	patients	use.	
These	strategies	range	
from	direct	limits	
(excluding	specific	
drugs	from	formulary,	
limiting	the	quantity	
covered)	to	rules	on	
utilization	
(formularies,	
preferred	drug	lists,	
prior	auth,	step	
therapy),	to	methods	
to	influence	how	
much	the	patient	pays	
(tiered	copayments,	
reference	pricing).
Pricing	Approaches	Available	to	All	Payers Lower	Transaction	Costs
Use	of	purchasing	pools Incentives	for	inc	use	of	mail-order	pharmacies
Higher	rebates	through	market	leverage Mandatory	mail	order	for	maintenance	meds
Requirements	to	make	prices	and	rebates	transparent
Lower	dispensing	fees	to	the	pharmacy
Use	of	restricted	pharmacy	networks
Use	of	discount	cards
Defined	contribution	approaches
Pricing	Strategies Market-based	
approaches	intended	
to	reduce	the	price	of	
drugs,	including	
restricted	pharmacy	
networks,	use	of	mail-
order	pharmacy	and	
manufacturer	rebates.
Pricing	Approaches Direct	Regulatory	Approaches
Expanded	access	to	Medicaid	rebates	or	changes	to	
the	rebate	formula
Broader	availability	of	generic	drugs	through	changing	
patent	protection	laws
Direct	price	regulation Broader	authority	to	move	drugs	to	OTC	status
Expanded	access	to	the	federal	supply	schedule Increased	regulations	of	direct-to-consumer	
advertising
Reduced	restrictions	on	importation	of	drugs	from	
other	countries
Regulatory	Strategies	Available	Only	to	Government Ways	of	using	gov't	
authority	to	contain	
costs,	including	direct	
price	regulation,	
changing	patent-
protection	laws,	
transferring	drugs	to	
OTC	status.
